Cleveland Clinic Performs Second Face Transplant (Video)
In a 24.5-hour surgery in late September, nine Cleveland Clinic surgeons and multiple specialists performed the hospital’s second face transplant on a middle-aged man who suffered severe facial trauma and other complications from a car accident. Advertising Policy Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We … Read More
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
The surgery included transplantation of about two-thirds of the scalp, the forehead, upper and lower eyelids, eye sockets, nose, upper cheeks, upper jaw, upper teeth, facial nerves, salivary glands, facial muscles, and skin, effectively replacing about 90 percent of the patient’s face.
“I am grateful beyond words to the donor and his family for their amazing gift,” said the patient, who wishes to remain anonymous. “I thank the Lord for the strength he’s given all of us to carry us through this, because we couldn’t do this on our own. I would like to thank the Cleveland Clinic – all the surgeons and staff who helped me, so many talented hands helping me in so many ways. I learned through this process that it’s so important that we raise awareness about organ and tissue donation. Your driver’s license donor card is not enough; please talk to your loved ones about your further donation wishes. God bless us all.”
“This was a case of cooperative surgical innovation,” said Dr. Papay. “This is a team sport and the patient is the most important part of the team; there is nothing more rewarding than making a profound difference in a patient’s life.”
The patient became a candidate for a face transplant after multiple attempts at facial reconstruction failed to correct his facial disfigurement or to improve his quality of life, as he still had difficulty breathing and speaking. A face transplant, by restoring eyelids, also offered a better chance to save the limited eyesight in his one eye that remained after the trauma.
Since the surgery, the patient is recovering well. He is now breathing without a tracheostomy and will begin eating orally shortly. His limited eyesight has been preserved, making this the first face transplant to successfully save a patient’s vision.
Doctors continue to monitor him closely for signs of tissue rejection and are adjusting his immune suppression accordingly. As with any organ transplant, the patient will be on lifelong immunosuppressive drugs. However, unlike most patients, his immune system was already medically suppressed, due to an underlying autoimmune condition.
To protect the privacy of those involved, no further information will be released about the patient, the donor or their families.
In December 2008, Cleveland Clinic became the first U.S. hospital to perform a face transplant. At the time, it was considered the largest and most complex face transplant in the world, integrating different functional components such as nose and lower eyelids, as well as different tissue types including, skin, muscles, bony structures, arteries, veins and nerves.
“Our face plays a central role in our identity – how we see ourselves and how others see us. Those who suffer facial trauma or disfigurement have physiological, psychological, and social difficulties,” said Dr. Siemionow, who, as the former director of Cleveland Clinic’s Department of Plastic Surgery Research, prepared Cleveland Clinic’s face transplant protocol in 2004. She is now a professor of orthopedic surgery at the University of Illinois at Chicago College of Medicine and acted as a consultant and advisor on the recent surgery. “A face transplant is not just an aesthetic surgery. It is a functional surgery, which will ultimately allow the patient to eat, speak, smell, smile, kiss, and feel welcome into society again.”
Cleveland Clinic is one of three U.S. institutions that has conducted face transplants. Fewer than three dozen face transplants have been performed worldwide. This most recent face transplant was supported by the U.S. Department of Defense’s Armed Forces Institute of Regenerative Medicine I (AFIRM I) grant program. As an integral part of the AFIRM, the Rutgers-Cleveland Clinic Consortium (RCCC) is committed to delivering advances in regenerative medicine that will improve the treatment of U.S. service members wounded on the battlefield. Through the RCCC, Dr. Siemionow has served as the primary investigator of this clinical trial.
“I was involved in advocating for the face transplants as a treatment option from the very beginning,” said Dr. Joachim Kohn, Director of the RCCC of the AFIRM I and Board of Governors Professor at Rutgers University. “Without the support of the DoD and the AFIRM, the United States as a nation would have fallen way behind the global effort to restore form and function to patients with severe facial injuries. I am therefore extremely pleased that Cleveland Clinic was able to perform this face transplant. We, at Rutgers University, have been administering and managing the contractual arrangement of this project and are fully supportive of this effort. Assuming a suitable patient and donor can be identified, we are able to support one additional face transplant under the current AFIRM I program.”
None of this would have been possible without the involvement of Lifebanc, Northeast Ohio’s nonprofit organ and tissue recovery organization.
“In keeping with Lifebanc’s mission of helping to improve and save the lives of others, we worked closely with the Cleveland Clinic on this exceptional case to ensure that the highest medical and ethical standards were met,” said Lifebanc CEO Gordon Bowen. “Since this was such a unique case, we collaborated with the Cleveland Clinic to develop a specific consent procedure, above and beyond the normal organ and tissue donation authorization process and limited to just this one situation. No one who is a registered organ, eye and tissue donor is affected by this specialized and limited consent process.”
Funding Acknowledgement This work was supported by the Army, Navy, NIH, Air Force, VA and Health Affairs to support the AFIRM I effort, under Award No. W81XWH-08-2-0034. The U.S. Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick MD 21702-5014 is the awarding and administering acquisition office. Dr. Joachim Kohn is the Principal Investigator of the prime contract to Rutgers University. This work was conducted under a subcontract from Rutgers University to the Cleveland Clinic. Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Department of Defense.